Sentrale fagmiljøer og helsepolitikere møttes på Oslo Cancer Clusters første åpne møte under Arendalsuka. De diskuterte hva persontilpasset medisin har potensial til å være – og hva som skal til for å oppnå resultater av forskning og klinisk bruk. Hva er egentlig persontilpasset medisin? Det handler enkelt forklart om at forebygging og behandling av sykdom […]
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 281 entries.
Entries by oslocancer
Interested pupils at Ullern Upper Secondary School arrive at laboratory 117 to learn alongside Dr. Bora Sieng, a chemist in Arctic Pharma. Dr. Sieng advocates for the importance of chemistry and encourages pupils to pursue a career in the exciting field of chemistry. At nine o’clock in the morning, three boys eagerly gather outside laboratory room 117. They’re […]
What kind of work does it take to receive PERMIDES funding for innovative concepts and projects? Meet one of the companies that just received funding. 22 collaboration projects will receive a total of 1,25 Million Euros from PERMIDES for innovation projects between small and medium sized enterprises (SMEs) from biopharma, bioinformatics and the IT […]
The project DoMore! aims to achieve better and faster diagnosis and prognosis with information and communication technology solutions. Technological innovation brightens the future ahead. With an increase in investment towards these areas, we create not only further potential in the technological field, but see betterment in the area it was produced for – such […]
The Department of Cellular Therapy is great at transforming cancer research into new companies. The latest spin-out is Zelluna. The Department of Cellular Therapy at the Radium Hospital, Oslo University Hospital, features one of Europe’s largest and most modern good manufacturing practice (GMP) facilities for cellular products. Head of the department is Prof. Gunnar Kvalheim. They […]
24 oncology innovators from 9 international hubs attended the 6th International Cancer Cluster Showcase in San Diego. The International Cancer Cluster Showcase (ICCS) was born back in 2011 in Washington DC, during the world’s largest biotech conference, BIO International Convention. International cluster managers and representatives from the oncology field in Boston, Toulouse and Oslo […]
Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway by being a significant partner for international clusters, global biopharma companies and academic centres. – Our goal is to support our members in their effort to attract international partners, investments and successful academia-industry collaborations, says International Advisor Jutta Heix. Heix is […]
Our newest board members are officially introduced! On the 24th of May in 2017, the general assembly meeting took place and fatefully decided Oslo Cancer Cluster’s newest board members. These members, despite having some big seats to fill, will take on a respectful duty belonging to the board: where professionals in the field function as the […]
Doctors, researchers and audience gather at breakfast to learn about genetics, data and how working together will help beat cancer. The time is 8:15. Many have started to file in and shuffle to their seats while chatting and occasionally sipping their first morning coffee. As it starts to quiet down, the lights are dimmed, the […]
A driving force behind the collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster is stepping down. This is her adventure. After fifteen great and productive years at Ullern Upper Secondary School, Esther Eriksen steps down from her position as vice principle in the upcoming month. Esther, who has been responsible for many various […]
Contact Team >
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.